Zai Lab Limited (NASDAQ:ZLAB) Insider Rafael Amado Sells 7,583 Shares

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares in the company, valued at $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $25.30 on Friday. The stock has a market capitalization of $2.77 billion, a P/E ratio of -9.13 and a beta of 1.00. Zai Lab Limited has a one year low of $13.48 and a one year high of $36.60. The firm’s 50 day simple moving average is $27.98 and its two-hundred day simple moving average is $23.05.

Institutional Trading of Zai Lab

Several institutional investors have recently added to or reduced their stakes in ZLAB. Janus Henderson Group PLC grew its position in Zai Lab by 34.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after acquiring an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP increased its position in Zai Lab by 18.4% during the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after purchasing an additional 1,312,115 shares during the period. Bamco Inc. NY raised its stake in Zai Lab by 6.4% in the third quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock worth $46,023,000 after buying an additional 113,869 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after purchasing an additional 125,532 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in Zai Lab by 1.4% during the second quarter. TD Asset Management Inc now owns 221,970 shares of the company’s stock worth $3,847,000 after acquiring an additional 3,000 shares in the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on ZLAB shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a report on Friday, October 25th. JPMorgan Chase & Co. increased their target price on Zai Lab from $38.00 to $44.00 and gave the company an “overweight” rating in a research note on Monday, October 21st.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.